Chemotherapy-induced dermatological toxicity: Frequencies and impact on quality of life in women's cancers. Results of a prospective study

Supportive Care in Cancer

Volumn 16, Issue 3, 2008, Pages 267-273

  Hackbarth, Mark ^a   Haas, Norbert ^a   Fotopoulou, Christina ^a   Lichtenegger, Werner ^a   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alopecia; Chemotherapy; Dermatological side effects; Health related quality of life; PPE; Women's cancer

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CLEMASTINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; INSULIN; IRINOTECAN; PACLITAXEL; PHENPROCOUMON; RANITIDINE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; THYROXINE; TOPOTECAN; TREOSULFAN;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CONTROLLED STUDY; DARIER DISEASE; DERMATOMYCOSIS; DYSESTHESIA; ENDOMETRIUM CANCER; FEMALE; FISHER EXACT TEST; FLUSHING; HAND FOOT SYNDROME; HUMAN; HYPERHIDROSIS; LEUKONYCHIAS; MAJOR CLINICAL STUDY; NAIL DISEASE; ONCYCHOLISIS; OVARY CANCER; PETECHIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; SIDE EFFECT; SUBUNGUAL HEMATOMA; URTICARIA; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; VAGINA CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PREVALENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SKIN DISEASES; STATISTICS, NONPARAMETRIC;

EID: 41049092051     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0318-8     Document Type: Article

References (36)

1. Anonymous (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 16(11):3537-3541
2. Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C, Meszaros P, Rosso R (1997) Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 33(6):967-969
3. Chiewchanvit S, Noppakun K, Kanchanarattanakorn K (2004) Mucocutaneous complications of chemotherapy in 74 patients from Maharaj Nakorn Chiang Mai Hospital. J Med Assoc Thail 87(5):508-514
4. Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC (2000) Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142(4):808-811
5. Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C (1993) Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13(5C):1781-1783
6. DeSpain JD (1992) Dermatologic toxicity of chemotherapy. Semin Oncol 19(5):501-507
7. Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL (2004) Oral dexamethasone attenuates doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94(2):320-324
8. EORTC (2006) EORTC QLQ-C30 Questionnaire V3.0
9. Essex (2000) Caelyx, Wissenschaftliche Produktinformationen
10. Fitzpatrick JE (1993) The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 20(1):1-14
11. Flory SM, Solimando DA Jr, Webster GF, Dunton CJ, Neufeld JM, Haffey MB (1999) Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 33(5):584-586
12. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19(4):424-436
13. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312-3322
14. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18(17):3093-3100
15. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75(8):2169-2173
16. Halford S, Yip D, Karapetis CS, Strickland AH, Steger A, Khawaja HT, Harper PG (2001) A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, doxil) in the treatment of unresectable pancreatic carcinoma. Ann Oncol 12(10):1399-1402
17. Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK (2004) Hand-foot syndrome in patients treated with capecitabine- containing combination chemotherapy. J Clin Pharmacol 44(10):1166-1172
18. Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS (2000) Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 88(10):2367-2371
19. Israel VP, Garcia A, Roman L, Muderspach L (1999) Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 78:143-147
20. Korac B, Buzadzic B (2001) Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. J Dermatol Sci 25(1):45-52
21. Link CJ Jr, Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, Reed E (1995) Cutaneous manifestations of Taxol therapy. Invest New Drugs 13(3):261-263
22. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 44(4):303-306
23. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136(12):1475-1480
24. Makris A, Mortimer P, Powles TJ (1996) Chemotherapy-induced onycholysis. Eur J Cancer 32A(2):374-375
25. Molpus KL, Anderson LB, Craig CL, Puleo JG (2004) The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 93(2):513-516
26. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15(3):987-993
27. NCI (1999) Common Toxicity Criteria, Version 2.0. 2.0 ed: http://ctep.info.nih.gov
28. Obermair A, Binder M, Barrada M, Bancher-Todesca D, Asseryanis E, Kubista E (1998) Onycholysis in patients treated with docetaxel. Ann Oncol 9(2):230-231
29. Oskay-Oezcelik G, Lehmacher W, Könsgen D, Christ H, Kaufmann M, Lichtenegger W, Sehouli J (2007) Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. Ann Oncol 18(3):479-484
30. Park YH, Ryoo BY, Lee HJ, Kim SA, Chung JH (2003) High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy. Ann Oncol 14(11):1691-1692
31. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82(2):323-328
32. Salzberg M, Herrmann R (2000) Hand-foot syndrome (palmar-plantar erythrodysesthesia). Schweiz Med Wochenschr 130(40):1413-1416
33. Sehouli J, Oskay-Oezcelik G (2004) Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer. ASCO 2004
34. Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J, de Wit R (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66(1):83-87
35. Susser WS, Whitaker-Worth DL, Grant-Kels JM (1999) Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40(3):367-398 (quiz 399-400)
36. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W (2002) Caelyx/doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2(2):143-150